https://www.yiliao.com/index.php?action=history&feed=atom&title=NTRK1
NTRK1 - 版本历史
2026-04-18T20:39:07Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=NTRK1&diff=311627&oldid=prev
2025年12月29日 (一) 12:38 77921020
2025-12-29T12:38:14Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 12:38的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">320px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">350px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=NTRK1&diff=311626&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T12:37:23Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>NTRK1</strong>（Neurotrophic Receptor Tyrosine Kinase 1），全称为 <strong>神经营养受体酪氨酸激酶 1</strong>，编码高亲和力的神经生长因子受体 <strong>[[TrkA]]</strong>。在正常生理中，NTRK1 信号对于痛觉神经元和交感神经元的存活与分化至关重要；其胚系失活突变会导致<strong>先天性无痛症</strong>（CIPA）。在肿瘤学领域，NTRK1 与 NTRK2/3 一样，是精准医疗历史上里程碑式的“<strong>不限癌种</strong>”（Tissue-Agnostic）靶点。其致癌机制几乎完全依赖于染色体重排形成的<strong>[[基因融合]]</strong>（NTRK Fusions）。无论肿瘤来源何处，只要携带 NTRK 融合，患者通常都能对 <strong>[[TRK抑制剂]]</strong>（如拉罗替尼）产生惊人的深度缓解。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">NTRK1 (TrkA) · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:Protein_TrkA_Kinase_Structure.png|100px|TrkA 激酶结构域 (PDB 4YNE)]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">神经生长因子受体</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>NTRK1</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">基因全名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">Neurotrophic Receptor Tyrosine Kinase 1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">蛋白产物</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">TrkA (Tropomyosin receptor kinase A)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">常用别名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">TRK, TRK1, MTC, p140-TrkA</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">1q23.1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">4914</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">8031</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">OMIM</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">191315</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">P04629</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">主要配体</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">NGF (神经生长因子)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; color: #0f172a;">~140 kDa</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：伙伴介导的二聚化</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
正常情况下，TrkA 激酶的激活需要 NGF 配体结合诱导二聚化。但在肿瘤中，NTRK1 发生染色体重排，其 3' 端（激酶域）与某个 5' 端伙伴基因融合。<br />
</p><br />
<br />
<br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>组成性激活：</strong> 伙伴基因（如 <strong>TPM3</strong>, <strong>LMNA</strong>, <strong>MPRIP</strong>）通常含有二聚化结构域（如卷曲螺旋）。这迫使 TrkA 激酶域在没有 NGF 的情况下发生持续性的二聚化和自磷酸化，从而激活下游的 MAPK、PI3K 和 PLCγ 通路。</li><br />
<li style="margin-bottom: 12px;"><strong>致癌效力：</strong> 这种融合蛋白不仅驱动细胞增殖和存活，还能促进神经元样的分化。有趣的是，TRK 融合是肿瘤的<strong>主效驱动基因</strong>（Oncogenic Driver），往往与其他驱动突变（如 EGFR, KRAS, ALK）互斥。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：常见癌中的罕见，罕见癌中的常见</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
NTRK 融合的分布呈现出典型的“两极化”特征。对于任何晚期实体瘤患者，NTRK 都是值得检测的“彩票型”靶点。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">癌种类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">NTRK 融合频率</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床特征</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">婴儿纤维肉瘤 (IFS)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>>90%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">最经典的 NTRK 融合肿瘤（主要是 <strong>ETV6-NTRK3</strong>）。拉罗替尼的出现使其能够避免截肢等致残性手术，是儿科肿瘤的奇迹。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">分泌型乳腺癌 / 唾液腺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>>90%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">这种罕见亚型的定义性特征也是 ETV6-NTRK3 融合。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">甲状腺乳头状癌 (PTC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">~10-25%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">NTRK1/3 融合是继 BRAF 和 RAS 之后的第三大驱动因素，尤其在儿童或辐射相关病例中常见。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">常见实体瘤 (肺/肠/胰)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong><1%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">虽然比例极低，但由于基数大，贡献了最多的病例数。常见于 MSI-H 结直肠癌或无驱动基因的肺腺癌中。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：不限癌种的精准打击</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
TRK 抑制剂的获批是基于“篮子试验”（Basket Trial）的成功，即根据基因突变而非肿瘤来源来入组患者。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>第一代 TRK 抑制剂：</strong><br />
<ul style="margin-top: 5px;"><br />
<li><strong>[[拉罗替尼]] (Larotrectinib/Vitrakvi)：</strong> 高选择性 TRK 抑制剂。在成人和儿童实体瘤中，客观缓解率（ORR）高达 75-80%，且持久有效。</li><br />
<li><strong>[[恩曲替尼]] (Entrectinib/Rozlytrek)：</strong> 多靶点抑制剂（TRK/ROS1/ALK）。具有良好的血脑屏障穿透性，特别适用于伴有脑转移的患者。</li><br />
</ul><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>耐药与二代药物：</strong> 使用一代药物后，肿瘤常产生激酶域突变（如 <strong>G595R</strong> 溶剂前沿突变，类似于 ALK 的 G1202R）。<br />
<br><strong>下一代抑制剂：</strong> 如 <strong>[[Selitrectinib]]</strong> (LOXO-195) 和 <strong>[[Repotrectinib]]</strong>。它们设计紧凑，能够规避耐药突变产生的空间位阻，用于一代耐药后的治疗。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>不限癌种 (Tumor-Agnostic)：</strong> 一种基于生物标志物而非器官起源的药物审批模式，NTRK 抑制剂是该模式的典范。</li><br />
<li style="margin-bottom: 12px;"><strong>CIPA (先天性无痛症)：</strong> NTRK1 胚系失活突变导致的罕见遗传病，患者无法感知疼痛且无汗，揭示了 TrkA 在痛觉传导中的核心作用。</li><br />
<li style="margin-bottom: 12px;"><strong>NTRK2 / NTRK3：</strong> 同家族成员，分别编码 TrkB 和 TrkC，同样通过基因融合致癌，且共享治疗药物。</li><br />
<li style="margin-bottom: 12px;"><strong>IHC 筛查：</strong> 免疫组化可作为 NTRK 融合的初筛手段（TrkA/B/C 表达），但金标准仍是 NGS RNA 测序。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Drilon A, et al. (2018).</strong> <em>Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</em> <strong>New England Journal of Medicine</strong>. <br><br />
<span style="color: #475569;">[学术点评]：里程碑式研究。汇总了三个临床试验的数据，展示了拉罗替尼在 17 种不同肿瘤类型中高达 75% 的缓解率，确立了“不限癌种”治疗的范式。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Vaishnavi A, et al. (2013).</strong> <em>Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.</em> <strong>Nature Medicine</strong>. <br><br />
<span style="color: #475569;">[学术点评]：首次利用二代测序在肺癌中鉴定出 NTRK1 融合，并证明其对 TRK 抑制剂敏感，开启了肺癌 NTRK 靶向治疗的研究。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Doebele RC, et al. (2020).</strong> <em>Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.</em> <strong>The Lancet Oncology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：证实了恩曲替尼的全身及颅内疗效，使其成为另一款重要的广谱抗癌药，特别强调了其对脑转移的控制能力。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Indo Y, et al. (1996).</strong> <em>Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis.</em> <strong>Nature Genetics</strong>. <br><br />
<span style="color: #475569;">[学术点评]：遗传学经典发现。揭示了 NTRK1 胚系突变是 CIPA 的致病原因，从反面证明了 TrkA 信号对痛觉神经发育的必需性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Cocco E, et al. (2018).</strong> <em>NTRK fusion-positive cancers and TRK inhibitor therapy.</em> <strong>Nature Reviews Clinical Oncology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：全面综述。详细总结了 NTRK 融合的生物学机制、检测方法及耐药机制（如 G595R），是该领域的权威参考。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">NTRK1 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[拉罗替尼]] • [[恩曲替尼]] • [[基因融合]] • [[CIPA]] • [[不限癌种]] • [[Repotrectinib]] • [[ETV6-NTRK3]] • [[G595R]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020